Resistance to cancer immunotherapy in metastatic renal cell carcinoma.
Ontology highlight
ABSTRACT: The prognosis of metastatic clear cell renal cell carcinoma (mccRCC) has changed dramatically over the years with the emergence of immune checkpoint inhibitors (ICI) used alone, or in combination with another ICI, or with vascular endothelial growth factor receptor tyrosine kinase inhibitor. Although major response rates have been observed with ICI, many patients do not respond, reflecting primary resistance, and durable responses remain exceptional, reflecting secondary resistance. Factors contributing to primary and acquired resistance are manifold, including patient-intrinsic factors, tumor cell-intrinsic factors and factors associated with the tumoral microenvironment (TME). While some mechanisms of resistance are common to several tumor types, others are specific to mccRCC. Predictive
SUBMITTER: Moreira M
PROVIDER: S-EPMC8992500 | biostudies-literature | 2020 3rd Quarter
REPOSITORIES: biostudies-literature
ACCESS DATA